BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

Covalon Technologies Ltd. to Showcase Breakthrough Surgical Wound Care Product at the American College of Surgeons Clinical Congress


10/21/2011 12:34:27 PM

MISSISSAUGA, ON, Oct. 21, 2011 /PRNewswire/ - Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV), an advanced medical technologies company, today announced it will be presenting SurgiClear, its new breakthrough surgical wound care product at this year's American College of Surgeons Clinical Congress (ACS), running October 23 to 27, 2011 in San Francisco.

SurgiClear is a clear film dressing with a breakthrough antimicrobial silicone adhesive especially designed to reduce the instances of surgical site infections.

Surgical site infections occur when germs enter the body through the incision site after a surgical procedure. Treating surgical site infections is a costly burden to the healthcare system and can cause serious, and in certain cases, life-threatening complications for patients. According to the Journal of Infection Control and Hospital Epidemiology, treating surgical site infections accounts for up to $10 billion annually in healthcare expenditures in the United States alone.

SurgiClear is the first transparent film dressing that allows clinicians and patients to monitor the healing process of surgical sites while providing effective antimicrobial protection for up to seven days against the leading organisms that cause surgical site infections, with the aid of two antimicrobial compounds infused directly into the silicone adhesive.

"We are extremely excited to showcase SurgiClear at this year's ACS meeting," said Brian Pedlar, Covalon's Chief Executive Officer. "There has been great excitement and interest about SurgiClear from surgeons, and medical device companies who are looking to license breakthrough new products."

To learn more about Covalon's products and services, please visit us at booth 1938 in the San Francisco Moscone Convention Centre from October 23 to 27 or contact Brian Pedlar, CEO Covalon Technologies Ltd. at bpedlar@covalon.com.

About Covalon

Covalon Technologies Ltd. researches, develops and commercializes new healthcare technologies that help save lives around the world. Covalon's patented technologies, products and services address the advanced healthcare needs of medical device companies, healthcare providers and individual consumers. Covalon's technologies are used to prevent, detect and manage medical conditions in specialty areas such as wound care, tissue repair, infection control, disease management, medical device coatings and biocompatibility. To learn more about Covalon, visit our website at www.covalon.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "plan, "estimate", "expect", "intend" and statements that an event or result "may", "will", "should", "could" or "might" occur or be achieved and other similar expressions. These forward-looking statements involve risk and uncertainties, including the difficulty in predicting product approvals, acceptance of and demands for new products, the impact of the products and pricing strategies of competitors, delays in developing and launching new products, the regulatory environment, fluctuations in operating results and other risks, any of which could cause results, performance, or achievements to differ materially from the results discussed or implied in the forward-looking statements. Many risks are inherent in the industry; others are more specific to the Company. Investors should consult the Company's ongoing quarterly filings for additional information on risks and uncertainties relating to these forward-looking statements. Investors should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update or alter any forward-looking statements whether as a result of new information, further events or otherwise.

SOURCE Covalon Technologies Ltd.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->